Medical AIFLOW: semaglutide and the kidney - in diabetic CKD.
In type 2 diabetes with chronic kidney disease, semaglutide 1.0 mg cut a composite of major kidney events plus cardiovascular death by about 24% (HR 0.76). The trial was stopped early for efficacy and led to the Ozempic kidney label expansion.
FLOW is the dedicated kidney-outcome trial of semaglutide. It randomized 3,533 adults with type 2 diabetes and chronic kidney disease to once-weekly semaglutide 1.0 mg or placebo, on top of standard care, and followed them for major kidney and cardiovascular outcomes.[1,2]
The trial met its primary endpoint convincingly: semaglutide reduced the primary composite outcome by about 24% versus placebo, with a hazard ratio of 0.76 (95% CI 0.66 to 0.88).[1] The independent data monitoring committee recommended stopping the trial early when a prespecified interim analysis showed clear benefit.[1]
In type 2 diabetes with CKD, semaglutide 1.0 mg cut a composite of major kidney events plus cardiovascular death by about 24% (HR 0.76, 95% CI 0.66 to 0.88), and the trial stopped early for efficacy.[1] This supported the FDA expansion of the Ozempic label in January 2025.[3]
What the primary outcome measured
The primary outcome was a composite of major kidney disease events plus cardiovascular death, specifically: onset of kidney failure (dialysis, transplantation, or an eGFR below 15 mL/min/1.73 m2), at least a 50% reduction in eGFR from baseline, or death from kidney-related or cardiovascular causes.[1] Bundling kidney failure, steep eGFR decline, and vascular death into one endpoint captures the outcomes that matter most to patients with CKD.
FLOW at a glance. Effect estimates are for the primary composite outcome unless noted.
| Feature | FLOW |
|---|---|
| Population | Type 2 diabetes with chronic kidney disease |
| Intervention | Semaglutide 1.0 mg once weekly vs placebo |
| Randomized | 3,533 participants |
| Primary composite | Major kidney events (kidney failure, >= 50% eGFR decline) plus death from kidney-related or cardiovascular causes [1] |
| Primary result | HR 0.76 (95% CI 0.66 to 0.88); about 24% risk reduction [1] |
| Trial status | Stopped early for efficacy at interim analysis [1] |
A diabetic CKD population, not SELECT
FLOW is specific to type 2 diabetes with CKD. That framing is important: it is a different population from the SELECT cardiovascular trial, which studied semaglutide in people with overweight or obesity and established cardiovascular disease but without diabetes. The kidney-protection signal in FLOW should be read within its diabetic CKD population, and not generalized to nondiabetic CKD on the strength of this trial alone.[1,2]
The regulatory follow-through
On January 28, 2025, the FDA expanded the Ozempic (semaglutide) label to include reducing the risk of worsening kidney disease (kidney disease progression), kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease, based on FLOW.[3] That made semaglutide the first GLP-1 receptor agonist with this kidney indication.
A 24% reduction in major kidney events plus cardiovascular death, in diabetic CKD, with a trial stopped early for benefit - that is what moved semaglutide into kidney-protective labeling.- Section synthesis
The library is curated. The product is asked.
An outcome trial like FLOW raises practical questions: which patients, alongside which background therapy (SGLT2 inhibitors, RAS blockade), and how the kidney and cardiovascular benefits stack. Ask, and read the trial.
This explainer is verified against the cited primary sources. Trial figures, the composite definition, and labeling details should be confirmed against the primary publication and current labeling before clinical use.
Medical AI returns evidence-grounded answers backed by real citations. It is a reference tool, and these terms describe how it should and should not be used.
01 Educational purpose
Medical AI is an information and reference tool intended for educational use only. The answers it returns are not medical advice, diagnosis, or treatment. Always consult a qualified doctor or healthcare professional with any question concerning a medical condition.
02 Professional use
Medical AI is designed for use by practicing clinicians. It is not intended for direct patient use and is not a substitute for professional clinical judgment. Apply your own training and current guidelines to every decision an answer informs.
03 Privacy and data
We do not collect, store, or process personally identifiable patient information (PHI or PII). Do not enter names, dates of birth, medical record numbers, or any other patient identifiers into the composer.
04 Information currency
Medical knowledge evolves rapidly. Citations carry their publication date, so consult the primary source and the most recent clinical guideline before acting on anything material.